Minghe Lv. (2023). MYL5 as a Novel Prognostic Marker is Associated with Immune Infiltrating in Breast Cancer: A Preliminary Study. Hindawi-Wiley.
Chicago Style (17th ed.) CitationMinghe Lv. MYL5 as a Novel Prognostic Marker Is Associated with Immune Infiltrating in Breast Cancer: A Preliminary Study. Hindawi-Wiley, 2023.
MLA (9th ed.) CitationMinghe Lv. MYL5 as a Novel Prognostic Marker Is Associated with Immune Infiltrating in Breast Cancer: A Preliminary Study. Hindawi-Wiley, 2023.
Warning: These citations may not always be 100% accurate.